Eaton Vance Ohio Municipal Income Trust (EVO)

HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.

HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth.

The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer

Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities

Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations

Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business

Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology

HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.

Advances made in preclinical pipeline addressing neurodegenerative diseases

Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz

Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms